Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation

Figure 1

HE and IHC of histopathology. Histopathology of biopsy of the breast. (a) and (b) show HE staining. Poorly differentiated malignant cells invading stromal areas. (c) shows an IHC positive for AE1/3, which rules out sarcoma. (d)–(f) show negative IHCs for GATA3, SOX100, and S100. These results exclude malignant melanoma.

(a) HE (4x objective)

(b) HE (40x objective)

(c) GATA3 (40x objective)

(d) AE1/AE3 (40x objective)

(e) SOX10 (40x objective)

(f) S100 (40x objective)